Q4 & Full Year 2025 Financial Results March 12, 2026 Disclaimer This Presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), capital expenditures, the introduction of new products, market strategy a ...

Core Viewpoint - Sisram Medical Ltd will announce its audited consolidated results for the year ended December 31, 2025, on March 23, 2026, followed by an earnings conference call on March 24, 2026, to discuss the financial results [1]. Group 1: Company Overview - Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD) [1]. - The company offers a synergistic ecosystem that includes EBD technologies, injectables, diagnostics, and complementary solutions, serving customers in over 110 countries and regions [1]. - Sisram Medical is majority-owned by Fosun Pharma and has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017 [1]. Group 2: Earnings Announcement Details - The earnings conference call will feature prepared remarks from key management, including the Chairman, CEO, Co-CEO and CFO, Secretary of the Board, and Investor Relations Director [1]. - Participants can join the conference calls by completing online registration prior to the scheduled call start time, with sessions available in both Chinese and English [1]. - A replay of the conference calls will be accessible on the company's website shortly after the events [1].

Core Viewpoint - So-Young International Inc. will report its financial results for Q4 and full year 2025 on March 25, 2026, before U.S. markets open [1] Group 1: Financial Reporting - The earnings conference call is scheduled for March 25, 2026, at 7:30 AM U.S. Eastern Time [1] - Dial-in details for the earnings conference call include international and local numbers for China, the U.S., and Hong Kong [1] - A telephone replay of the conference call will be available two hours after its conclusion until April 1, 2026 [1] Group 2: Company Overview - So-Young is the leading aesthetic treatment platform in China, connecting consumers with online services and offline treatments [1] - The company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information and facilitating online reservations [1] - So-Young is positioned to grow along the medical aesthetic value chain due to its strong brand recognition, digital reach, affordable treatments, and efficient supply chain [1]

Core Insights - The Beauty Health Company is expanding its professional skin health ecosystem through the growing adoption of Hydrafacial treatments and SkinStylus Nano-Channeling protocols to meet rising consumer demand for combination treatments [1][2] Industry Trends - There is an increasing demand for combination protocols that provide enhanced results without downtime, with 77% of providers reporting higher client satisfaction and 81% of consumers willing to pay more for combination therapies [4] - In the U.S., 52% of combination protocols already incorporate microdermabrasion treatments like Hydrafacial [4] Treatment Details - SkinStylus Nano-Channeling is a non-invasive treatment that creates nano-channels in the skin to improve the appearance of fine lines, wrinkles, and overall skin quality, especially when paired with Hydrafacial treatments [3][5] - The combined treatment begins with a Hydrafacial session followed by SkinStylus Nano-Channeling, enhancing product delivery and treatment performance, resulting in immediate glowing skin with no downtime [5] Provider Adoption - Provider adoption of SkinStylus Nano-Channeling is accelerating, with LifeSpa at Life Time expanding its service offerings following a successful pilot program [6] - The SkinStylus device can be used for either microneedling or nano-channeling, depending on the provider's qualifications, with nano-channeling primarily aimed at enhanced product infusion [7] Company Overview - The Beauty Health Company (NASDAQ: SKIN) is a global medical aesthetics company focused on delivering clinically proven solutions for superior skin health, anchored by its flagship Hydrafacial treatment [9]

Core Insights - Visionary Holdings Inc. is focusing on expanding its presence in the global healthcare and medical aesthetics markets, particularly in North America and Europe, as part of its strategic growth priorities for 2026-2027 [1][2][4] Business Outlook - The period from 2026 to 2027 is expected to be crucial for the commercialization of the RAMU anti-aging product line, which is anticipated to drive significant revenue growth [4][9] - Management estimates that RAMU-related product sales could potentially reach approximately US$30 million annually, depending on market conditions and operational execution [5] Strategic Growth Priorities - The company plans to continue its expansion into international medical aesthetics markets through product commercialization, distribution partnerships, and healthcare service collaborations [7] - Visionary aims to accelerate the commercialization of its RAMU anti-aging product line, targeting premium applications in medical aesthetics and regenerative healthcare [7] - Development of integrated healthcare service platforms that combine medical aesthetics products, wellness services, and advanced biotechnology applications is also a priority [8] Management Commentary - The CEO of Visionary Holdings emphasized the importance of the upcoming period for the company's strategic transition towards healthcare services and medical aesthetics, highlighting the potential for meaningful growth opportunities [9][10]

Core Insights - The company achieved a 12% full-year revenue growth despite a decline in U.S. injectable volumes for only the third time in 25 years [1] - Jeuveau captured a 14% market share through a 'beauty-first' strategy that focuses on cash-pay aesthetic practices rather than reimbursement models [1] - The company successfully piloted a new portfolio growth rebate program to incentivize accounts to consolidate toxin and filler spending with Evolus [1] Financial Performance - International revenue nearly doubled year-over-year, driven by a transition to a direct model in Germany and approaching double-digit market share in the U.K. [1] - A structural expense reset was executed in mid-2025 to align the organization for durable, profitable growth and meaningful operating leverage [1] Product and Market Strategy - The Evolysse HA filler footprint expanded to over 3,000 purchasing accounts, utilizing Cold-X Technology to meet consumer demand for natural-looking results [1] - The company maintained brand resilience through Evolus Rewards, an SMS-based loyalty program that has grown to over 1.4 million treated patients [1]

Financial Data and Key Metrics Changes - Global net revenue for Q4 2025 was $90.3 million, representing a 14% growth over Q4 2024, including $83.1 million from Jeuveau and $7.2 million from Evolysse [14][15] - For the full year 2025, global net revenue was $297.2 million, up 12% compared to 2024, marking the sixth consecutive year of double-digit growth [15][11] - Reported gross margin for Q4 was approximately 66%, with adjusted gross margin at approximately 67% [16] - GAAP operating expenses for Q4 were $55.1 million, down from $57.3 million in Q3, while non-GAAP operating expenses were $53 million, compared to $49.7 million in Q3 [17][18] - Non-GAAP operating income for Q4 was $7.1 million, compared to $6.7 million in Q4 2024 [19] Business Line Data and Key Metrics Changes - Jeuveau captured over 14% U.S. market share, continuing to gain share even in a declining procedural environment [9] - Evolysse, introduced in 2025, has over 3,000 customers, expanding the company's presence within accounts [10] - International revenue nearly doubled year-over-year, now representing approximately 8% of total revenue, with strong growth in markets like the U.K. [15][10] Market Data and Key Metrics Changes - The U.S. injectable procedural volumes declined for only the third time in 25 years, yet Evolus achieved 12% revenue growth in 2025 [11] - The neurotoxin market declined mid to upper single digits in 2025, but Jeuveau gained units despite new competition [56] - The filler market is expected to see low single-digit growth, with signs of recovery anticipated [56][88] Company Strategy and Development Direction - Evolus aims to build a global performance beauty company centered on differentiated brands for cash pay consumers, with a focus on expanding its product portfolio [12][26] - The company plans to introduce Estyme in Europe in Q2 2026 and expects FDA approval of Evolysse Sculpt in Q4 2026 [12][26] - Evolus is committed to driving profitable growth, targeting revenue between $450 million to $500 million by 2028 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustained profitability beginning in 2026, with a low to mid-single-digit adjusted EBITDA margin expected [12][25] - The company noted that the aesthetic market is showing signs of recovery, particularly in the filler market, with expectations for gradual improvement [56][88] - Management highlighted the importance of customer loyalty programs and the positive feedback received from clinicians regarding product differentiation [32][56] Other Important Information - Evolus has entered into a revolving credit facility providing up to $30 million for working capital needs [21] - The company is not planning to raise equity capital and remains sensitive to dilution [22] Q&A Session Summary Question: Has the growth of Evolus been primarily from early adopters? - Management noted that the customer base is diversifying, with over 3,000 purchasing accounts contributing to revenue growth [30] Question: Can Evolus turn around market growth impacted by macro trends? - Management believes that while macro factors affect the market, there are signs of improvement in the filler market [34] Question: Can you provide details on the rebate program structure? - The rebate program is designed to reward clinics for increased purchases, with eligibility based on quarterly purchase volumes [42][43] Question: How is the overall marketing strategy described for 2026? - The marketing strategy includes digital advertising and co-promotions with beauty brands, tailored to individual clinics [46][47] Question: What are the assumptions regarding competitive launches in guidance? - Management acknowledged the expected launch of new competitors in 2026 but remains confident in their product differentiation and market position [62][80]

INVESTOR PRESENTATION MARCH 2026 2 This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product and product candidates; the potential market ...

Core Insights - Visionary Holdings Inc. has signed a US$12 million exclusive distribution agreement for its anti-aging product, Premier Regenerative Complex – President Super Injection, with Huajin China Investment Company, while divesting its non-core education business [1][3][5] - The company is transitioning into a commercialization acceleration phase within the high-end medical aesthetics sector [2] Commercialization Milestone - The exclusive distribution agreement establishes a minimum sales target of US$12 million within 12 months, with revenue recognition contingent on product delivery and customer acceptance [3][4] - This agreement signifies a significant step in scaling the commercial deployment of the Premier Regenerative Complex, reflecting increased market acceptance and enhanced revenue visibility [4][8] Strategic Divestiture - The Board of Directors approved the divestiture of Visionary Education Services & Management Inc., marking a complete exit from non-core operations [5] - This strategic move allows Visionary Holdings to focus exclusively on biotechnology and healthcare, enhancing capital efficiency and financial flexibility [8] Management Commentary - The CEO of Visionary Holdings emphasized that the company is entering a focused growth phase in the global medical aesthetics market following the completion of its core business refocusing [6][8] - The company has identified medical aesthetics and regenerative injectable products as its long-term core growth engine, aiming for improved revenue visibility and operational focus [7][9] About Huajin China - Huajin China Investment Company operates over 900 health and wellness centers across China, focusing on community-based smart elderly care and health management [10] - The company aims to become a leading AI-driven digital elderly care platform in the Asia-Pacific region through industry consolidation and capital market integration [10] About Visionary Holdings Inc. - Visionary Holdings Inc. is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions, headquartered in Toronto, Canada [11]

Core Viewpoint - The Beauty Health Company will report its fourth quarter and full year 2025 financial results on March 12, 2026, after market close, followed by an investor conference call [1]. Group 1: Financial Reporting - The financial results will be announced after market close on March 12, 2026 [1]. - An investor conference call is scheduled for 4:30 p.m. Eastern Time on the same day [1]. Group 2: Access to Information - A live webcast of the investor call will be available on the Company's investor relations website [2]. - A recording of the call will be accessible approximately three hours after its conclusion [2]. Group 3: Company Overview - The Beauty Health Company (NASDAQ: SKIN) is a global medical aesthetics company focused on skin health solutions [4]. - The flagship brand, Hydrafacial™, is a leading professional skincare treatment, complemented by offerings like SkinStylus™ microneedling and HydraScalp powered by Keravive™ [4]. - The company combines advanced device technology, proprietary consumables, and clinical validation to provide trusted treatment experiences through a global network of providers [4].